Summary:
Predicta Biosciences is developing non-invasive blood tests for multiple myeloma, a type of blood cancer.
GenoPredicta, the company's lead product, analyzes blood samples to identify DNA specific to myeloma tumors.
Predicta secured $5.2 million in seed funding to advance its technology and launch GenoPredicta in early 2025.
The company plans to expand its offerings to diagnose other cancers and develop ImmunoPredicta to monitor the immune system.
Despite the potential of blood tests for cancer detection, skepticism remains among physicians, but Predicta's founders believe their research will help educate doctors and patients about the benefits of their technology.
Predicta aims to bridge the gap between research and clinical practice by offering actionable data that directly impacts patient care.
Blood Tests for Cancer: A New Era in Early Detection?
Predicta Biosciences, a precision oncology company, is developing non-invasive blood tests to diagnose and monitor multiple myeloma, a type of blood cancer affecting over 35,000 Americans annually.
The company's technology, GenoPredicta, analyzes blood samples to identify DNA specific to multiple myeloma tumors, offering a more convenient and less invasive alternative to traditional bone marrow biopsies.
Predicta recently secured $5.2 million in seed funding to advance its technology and launch GenoPredicta in early 2025. The company plans to expand its offerings to diagnose other cancers and develop a second product, ImmunoPredicta, to monitor the immune system in multiple myeloma patients.
Despite the potential of blood tests for cancer detection, skepticism remains among physicians. The FDA has only approved two blood tests for solid tumors, and none for blood cancers. However, Predicta's founders believe their research, backed by a published paper in Cancer Discovery, will help educate doctors and patients about the benefits of their technology.
Predicta's approach is unique in its focus on providing actionable data to both physicians and patients. The company aims to bridge the gap between research and clinical practice by offering insights that directly impact patient care.
Comments